ReviewEcancermedicalscience2018
Surgery for
Review in Ecancermedicalscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Heritability of Low ER Staining/HER2-Breast Tumors: Are We Missing an Opportunity for Germline Testing?Genes · 2020Trial
- Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?Breast (Edinburgh, Scotland) · 2023Article
- BRCA1 and BRCA2 mutations and their clinical relevance in selected women diagnosed with triple-negative breast cancer in Kenya: a descriptive cross-sectional study.The Pan African medical journal · 2023Article
- Significance ofOxidative medicine and cellular longevity · 2022Article
- Risk-reducing surgery inTranslational breast cancer research : a journal focusing on translational research in breast cancer · 2022Article
- Management of patients with BRCA mutation from the point of view of a breast surgeon.Annals of medicine and surgery (2012) · 2021Review
- Article
- Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.Annals of surgical oncology · 2020Article
- Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients.Archives of gynecology and obstetrics · 2020Article
- Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Identification of a four-long non-coding RNA signature in predicting breast cancer survival.Oncology letters · 2020Article
- Significant random signatures reveals new biomarker for breast cancer.BMC medical genomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe presence of a deleterious mutation, most commonly a METHODOLOGY: A search was done on PubMed, limited to reviews and the English language only. The search terms used were '
resultsBreast-conserving surgery has equivalent survival, but may have an increased risk of local recurrence, compared to mastectomy among
conclusionA comprehensive approach is needed to provide optimum treatment for breast cancer patients with deleterious mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.